Hospitalised infections and rituximab administration among children and adolescents with systemic lupus erythematosus from 2009 to 2021
Authors' conclusion
In this cohort of patients with cSLE who received inpatient treatment with rituximab, we observed a 14% rate of hospitalisation with infection in the year following rituximab administration among youth with cSLE. Rituximab use declined during the COVID-19 pandemic. No fatalities with COVID-19 were observed.
Study context
- Population
- Youth ages 2–21 years with childhood-onset SLE who received rituximab during admission to a Pediatric Health Information System hospital, 2009 to 2021
- Participants
- 1,567 participants
- Outcome
- Incidence of infections requiring hospitalisation following first rituximab administration
- Follow-up
- 12 months
Methodological detailslongitudinal, Pediatric Health Information System hospitals
- Longitudinal
- Pediatric Health Information System hospitals
Main finding
As reported in the abstract
Children admitted with an infection within 1 year after first rituximab
219
Incidence rate of hospitalised infection
140 cases per 1000 patient-years
Observational data: associations, not effects.
Further findings
Most common hospitalised infections
- Bacterial pneumonia, sepsis and cellulitis
Hospitalisation with COVID-19
- Children hospitalised with COVID-19
- 12
- Deaths among those hospitalised with COVID-19
- 0
Hospitalisations with rituximab administered
- Decreased from 2019 to 2021
Death during a hospitalisation with an infection in the year after rituximab
- Children who died
- 7 (0.44%)
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →